The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Open accessAbstract
Purpose: TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor–copositive metastatic breast cancer (MBC). Patients and Methods: Postmenopausal women with HER2/hormone receptor–copositive MBC were randomly assigned to anastrozole (1 mg/d orally) with or without trastuzumab (4 mg/kg intravenous infusion on day 1, then 2 mg/kg every week) until progression. The primary end point was progression-free survival (PFS) in the intent-to-treat population. Results: Overall, 103 patients received trastuzumab plus anastrozole; 104 received anastrozole alone. Patients in the trastuzumab plus anastrozole arm experienced significant improvements in PFS compared with patients receiving anastrozole alone (hazard ratio = 0.63; 95% CI, 0.47 to 0.84; median PFS, 4.8 v 2.4 months; log-rank P = .0016). In patients with centrally confirmed hormone receptor positivity (n = 150), median PFS was 5.6 and 3.8 months in the trastuzumab plus anastrozole and anastrozole alone arms, respectively (log-rank P = .006). Overall survival in the overall and centrally confirmed hormone receptor–positive populations showed no statistically significant treatment difference; however, 70% of patients in the anastrozole alone arm crossed over to receive trastuzumab after progression on anastrozole alone. Incidence of grade 3 and 4 adverse events was 23% and 5%, respectively, in the trastuzumab plus anastrozole arm, and 15% and 1%, respectively, in the anastrozole alone arm; one patient in the combination arm experienced New York Heart Association class II congestive heart failure. Conclusion: Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor–copositive MBC compared with anastrozole alone, although adverse events and serious adverse events were more frequent with the combination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
WHO handbook for reporting results of cancer treatment
Sylvester, R. (1980) · Controlled Clinical Trials · doi:10.1016/0197-2456(80)90009-4 · Cited by 1,055
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.142 · Cited by 588
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Rolski, J., Chan, A., Mackey, J., Liu, M., Pinter, T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-62 · Cited by 553
Self-citationOsborne, C. K., Shou, J., Massarweh, S., & Schiff, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.865s.11.2 · Cited by 462
Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., Cuzick, J., Houghton, J., Williams, N., Mallon, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9437 · Cited by 450
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Perez, E. A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L., Viens, P., Cai, C., Mullaney, B., Peck, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3849 · Cited by 393
De Laurentiis, M., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., Tortora, G., D'Agostino, D., Caputo, F., Cancello, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2569 · Cited by 340
Rhodes, A., Jasani, B., Barnes, D. M., Bobrow, L. G., & Miller, K. D. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.2.125 · Cited by 325
Schiff, R., Massarweh, S. A., Shou, J., & Osborne, C. K. (2003) · PubMed · Cited by 304
Lipton, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1467 · Cited by 253
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kauffman, P. A., & Wolmark, N. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.512 · Cited by 218
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
Untch, M., Gelber, R. D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn005 · Cited by 197
Dowsett, M., Harper-Wynne, C. L., Boeddinghaus, I., Salter, J., Hills, M., Dixon, M., Ebbs, S. R., Gui, G. P., Sacks, N., & Smith, I. E. (2001) · PubMed · Cited by 172
Marcom, P. K., Isaacs, C. J., Harris, L. N., Wong, Z. W., Kommareddy, A., Novielli, N., Mann, G., Tao, Y., & Ellis, M. J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9307-8 · Cited by 154
Mauriac, L., Keshaviah, A. P., Debled, M., Mouridsen, H. T., Forbes, J., Thurlimann, B. J. K., Paridaens, R., Monnier, A., Láng, I., Wardley, A. M., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm001 · Cited by 136
Self-citationSerum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Harvey, H. A., Chaudri‐Ross, H. A., Brady, C., Wyld, P. J., & Carney, W. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.098 · Cited by 124
Endocrine therapy in the treatment of metastatic breast cancer
Buzdar, A. U. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90122-8 · Cited by 101
First—select the target: better choice of adjuvant treatments for breast cancer patients
Goldhirsch, A., Coates, A. S., Gelber, R. D., Glick, J. H., Thurlimann, B. J. K., & Senn, H.-J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl398 · Cited by 97
Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody
Witters, L. M., Kumar, R., Chinchilli, V. M., et al. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005798224288 · Cited by 92
Johnston, S. R. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.889s.11.2 · Cited by 75
Historical perspective on hormonal therapy of advanced breast cancer
JORDAN, C. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85031-7 · Cited by 55
Jones, A. L. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg483 · Cited by 42
Self-citationMurray, J., Young, O. E., Renshaw, L., White, S. L., Williams, L. J., Evans, D. B., Thomas, J., Dowsett, M., & Dixon, J. M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0027-0 · Cited by 28
Hu, J., & Mokbel, K. (2001) · European Journal of Surgical Oncology · doi:10.1053/ejso.2000.1078 · Cited by 27
Penault-Llorca, F. M., Vincent‐Salomon, A., Mathieu, M. C., Trillet-Lenoir, V. N., Khayat, D., & Marty, M. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.764 · Cited by 18
ERBB2 status and outcome of endocrine treatment
Miller, W. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70389-3 · Cited by 5
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Metadata
- Authors
- Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., Révil, C., & Jones, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-20
- Volume
- 27
- Issue
- 33
- Pages
- 5529-5537
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140055441
- Cited by
- 843
- References
- 38
- FWCI
- 33.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.